Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland - supplementary material

Figure S1. Model schematic.Curves provided in this image are hypothetical to illustrate how health state occupancy is determined. OS: overall survival; PD: progressed disease; PF: progression free; PFS: progression-free survival.Figure S2. Parametric survival model extrapolations for OS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.Figure S3. Parametric survival model extrapolations for OS (BSC). BSC: best supportive care; KM: Kaplan-Meier; OS: overall survival.Figure S4. Log-cumulative hazard plot for OS. BSC: best supportive care; OS: overall survival.Figure S5. Standard parametric survival model extrapolations for PFS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S6. Standard parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S7. Spline-based parametric survival model extrapolations for PFS (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S8. Spline-based parametric survival model extrapolations for PFS (BSC). BSC: best supportive care; KM: Kaplan-Meier; PFS: progression-free survival.Figure S9. Log-cumulative hazard plot for PFS. BSC: best supportive care; PFS: progression-free survival.Figure S10. Extrapolations for TTD (avelumab + BSC). BSC: best supportive care; KM: Kaplan-Meier; TTD: time to treatment discontinuation.Table S1. Statistical goodness-of-fit scores for OS.Table S2. Statistical goodness-of-fit scores for PFS.Table S3. Model parameters.